BECTON DICKINSON & CO
BDX
44 insider filings · Latest: Sep 28, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Sep 30 1:13 AM | Michael FeldEVP, Chief Revenue Officer | Sale | 76 | $183.70 | $14.0K | 19,644(D) | View → |
| Sep 28, 2026 | Sep 28 8:21 PM | MICHAEL FELD | Proposed Sale | 76 | $183.82 | $14.0K | — | View → |
| Aug 26, 2026 | Aug 27 8:28 PM | Michael FeldEVP, Chief Revenue Officer | Sale | 165 | $188.49 | $31.1K | 19,720(D) | View → |
| Aug 26, 2026 | Aug 26 8:17 PM | MICHAEL FELD | Proposed Sale | 165 | $189.78 | $31.3K | — | View → |
| Aug 20, 2026 | Aug 20 8:13 PM | RICHARD BYRD | Proposed Sale | 1,330 | $187.97 | $250.0K | — | View → |
| Aug 13, 2026 | Aug 14 8:36 PM | Thomas E Polen JrDirector, Chairman, CEO and President | Sale | 4,152 | $185.00 | $768.1K | 110,163(D) | View → |
| Aug 13, 2026 | Aug 13 8:32 PM | THOMAS POLEN | Proposed Sale | 4,152 | $183.58 | $762.2K | — | View → |
| Aug 11, 2026 | Aug 12 9:27 PM | Roland GoetteEVP and President, EMEA | Sale | 2,438 | $180.84 | $440.9K | 14,856(D) | View → |
| Aug 11, 2026 | Aug 11 3:58 PM | Roland Goette | Proposed Sale | 2,438 | $180.84 | $440.9K | — | View → |
| Aug 3, 2026 | Aug 3 8:17 PM | SHANA NEAL | Proposed Sale | 1,500 | $165.62 | $248.4K | — | View → |
| Jul 27, 2026 | Jul 28 3:16 PM | Michael FeldEVP, Chief Revenue Officer | Sale | 75 | $157.13 | $11.8K | 20,934(D) | View → |
| Jul 27, 2026 | Jul 27 8:19 PM | MICHAEL FELD | Proposed Sale | 75 | $156.36 | $11.7K | — | View → |
| Jun 26, 2026 | Jun 27 12:47 AM | Michael FeldEVP, Chief Revenue Officer | Sale | 75 | $152.80 | $11.5K | 21,009(D) | View → |
| Jun 26, 2026 | Jun 26 8:26 PM | MICHAEL FELD | Proposed Sale | 75 | $151.38 | $11.4K | — | View → |
| Jun 24, 2026 | Jun 25 2:16 PM | Michael David GarrisonEVP & Pres Med.Essntl&BioPharm | Sale | 1,100 | $145.66 | $160.2K | 13,172(D) | View → |
| Jun 24, 2026 | Jun 24 8:38 PM | MICHAEL GARRISON | Proposed Sale | 1,100 | $143.92 | $158.3K | — | View → |
| Jun 10, 2026 | Jun 11 9:21 PM | Michael David GarrisonEVP & Pres Med.Essntl&BioPharm | Sale | 1,100 | $151.48 | $166.6K | 14,272(D) | View → |
| Jun 10, 2026 | Jun 10 8:29 PM | MICHAEL GARRISON | Proposed Sale | 1,100 | $152.04 | $167.2K | — | View → |
| Jun 1, 2026 | Jun 3 4:44 PM | Thomas E Polen JrDirector, Chairman, CEO and President | Sale | 2,764 | $146.35 | $404.5K | 110,163(D) | View → |
| Jun 1, 2026 | Jun 1 8:21 PM | THOMAS POLEN | Proposed Sale | 2,764 | $147.12 | $406.6K | — | View → |
Page 1 of 4
Next →
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Aug 14 8:36 PM | Thomas E Polen JrDirector, Chairman, CEO and President | Option Exercise | 43,278 | — | 0(D) | View → |
| Aug 6, 2026 | Aug 6 8:47 PM | Robert Luther HuffinesDirector | Grant/Award | 189 | — | 595(D) | View → |
| Aug 6, 2026 | Aug 6 8:47 PM | Carrie L ByingtonDirector | Grant/Award | 94 | — | 3,810(D) | View → |
| Jun 1, 2026 | Jun 3 4:44 PM | Thomas E Polen JrDirector, Chairman, CEO and President | Option Exercise | 20,209 | — | 0(D) | View → |
| May 8, 2026 | May 8 9:26 PM | Robert Luther HuffinesDirector | Grant/Award | 210 | — | 404(D) | View → |
| May 8, 2026 | May 8 9:25 PM | Carrie L ByingtonDirector | Grant/Award | 105 | — | 3,699(D) | View → |
| Feb 4, 2026 | Feb 5 5:24 PM | Robert Luther HuffinesDirector | Grant/Award | 100 | — | 100(D) | View → |
| Feb 4, 2026 | Feb 5 5:21 PM | Carrie L ByingtonDirector | Grant/Award | 30 | — | 1,714(D) | View → |
| Feb 4, 2026 | Feb 5 5:18 PM | Christopher Ian Montague JonesDirector | Grant/Award | 272 | — | 11,649(D) | View → |
| Jan 15, 2026 | Jan 16 8:43 PM | Michael David GarrisonEVP & Pres Med.Essntl&BioPharm | Option Exercise | 3,054 | $167.91 | 0(D) | View → |